A novel design of gold-coated iron oxide nanoparticles was fabricated as a potential delivery system to improve the efficiency and stability of d, l-sulforaphane as an anticancer drug. To this purpose, the surface of gold-coated iron oxide nanoparticles was modified for sulforaphane delivery via furnishing its surface with thiolated polyethylene glycol-folic acid and thiolated polyethylene glycol-FITC. The synthesized nanoparticles were characterized by different techniques such as FTIR, energy dispersive X-ray spectroscopy, UV-visible spectroscopy, scanning and transmission electron microscopy. The average diameters of the synthesized nanoparticles before and after sulforaphane loading were obtained * 33 nm and * 38 nm, respectively, when * 2.8 mmol/g of sulforaphane was loaded. The result of cell viability assay which was confirmed by apoptosis assay on the human breast cancer cells (MCF-7 line) as a model of in vitro-cancerous cells, proved that the bare nanoparticles showed little inherent cytotoxicity, whereas the sulforaphane-loaded nanoparticles were cytotoxic. The expression rate of the anti-apoptotic genes (bcl-2 and bcl-x L ), and the proapoptotic genes (bax and bak) were quantified, and it was found that the expression rate of bcl-2 and bcl-x L genes significantly were decreased when MCF-7 cells were incubated by sulforaphane-loaded nanoparticles. The sulforaphane-loaded into the designed goldcoated iron oxide nanoparticles, acceptably induced apoptosis in MCF-7 cells.
Introduction
Many studies confirmed that sulforaphane (SF) which was found in broccoli, cauliflower, kale and other cruciferous vegetables, and chemically was named 1-isothiocyanato-4-(methylsulfinyl)-butane, acts as an efficient incidence reducer in various types of tumors [1] [2] [3] . It has been revealed that SF has a promising and powerful anti-carcinogen effect in various cancers such as penicillin G, phosphate buffer (20 mM, pH = 7.8) and corresponding salts which were used throughout this research were obtained from Sigma-Aldrich or Merck. Fetal bovine serum (FBS) and Dulbecco's Modified Eagle's Medium (DMEM) as a culture medium and other supplements were obtained from Gibco (Germany).
MCF-7 cells were grown in DMEM medium supplemented with 10% (v/v) heat-inactivated FBS, 2% l-glutamine, 2.7% sodium bicarbonate, 1% Hepes buffer, and 1% penicillin-streptomycin solution (GPS, Sigma) at 37°C in humidified atmosphere with 5% CO 2 . Cells were trypsinized in the solution of 0.05% trypsin and seeded into 96-well micro-plates at the density of 1 × 10 5 cells/well. MCF-7 (human breast carcinoma) cell line was obtained from national cell bank of Iran (Pasteur institute, Iran) and cultured in DMEM medium containing 2 mM L-glutamine and 10% FBS, penicillin (50 IU/ml) and streptomycin (50 μg/ml). Cells were separated using 0.1% trypsin and 10 μM EDTA in phosphate-buffered solution.
The powder XRD spectrum was recorded at room temperature (RT) with a Philips X'pert 1710 diffractometer using Cu Kα (α = 1.54056 A). The morphologies of the NPs were observed using SEM (Hitachi S-4800 II, Japan) equipped with energy dispersive X-ray spectroscopy (EDX). The TEM analysis was performed on a Hitachi H-7650 (Japan) operating at an acceleration voltage of 80 kv. The IR spectra were taken using Nicolet FT-IR Magna 550 spectrographs applying spectroscopic grade KBr. The size of NPs was assessed by DLS (Nano-ZS 90, Malvern Instrument, United Kingdom). The temperature was kept at 25°C during the measuring process and measurements were recorded as the average of three test runs. The zeta potential of the NPs was measured in folded capillary cells using Nano sizer (Zeta sizer Nano ZS90, Malvern Instruments Ltd., Malvern, UK).
Synthesis of NH 2 -PEG-SH
Synthesis of α-tosyl-ω-hydroxyl PEG (I). To a solution of PEG (1450 g/mol, 3.45 mmol) in dry toluene, silver (I) oxide (5.2 mmol) and potassium iodide (0.7 mmol) were added, then p-toluene sulfonyl chloride (3.5 mmol) was added in one portion [36] . After 12 h stirring at RT, the mixture was filtered and the organic solvent evaporated. The product was dissolved in 10 ml dichloromethane (CH 2 Cl 2 ) and then precipitated by drop-wise addition into diethyl ether (Et 2 O) and I was filtered. 1 HNMR (DMSO): 7.79 (2H), 7.49 (2H), 4.56 (1H, OH), 4.11 (2H, CH 2 -OSO 2 ), 3.49 (bs, PEG backbone), 2.43 (3H, s, CH 3 ).
Synthesis of α-azide-ω-hydroxyl PEG (II). A mixture of I (3.0 mmol) and NaN 3 (4 mmol) in 150 ml of dry DMF was stirred overnight at 90°C under argon atmosphere. The mixture was cooled down, filtered, and DMF was removed under vacuum. The product was dissolved in CH 2 Cl 2 and washed twice with brine and water. The organic phase was dried over sodium sulfate and reduced to a small volume, and finally precipitated by dropping into Et 2 O. Then II was filtered.
1 H-NMR (DMSO): 4.56 (1H, OH), 3.6 (2H, OCH 2 ), 3.5 (bs, PEG backbone), 3.4 (2H, CH 2 -N 3 ) [36] . Synthesis of α-azide-ω-thioacetate PEG (III). To a mixture of II (3.0 mmol) in 100 ml CH 2 Cl 2 were added NEt 3 (10.0 mmol) and TsCl (10.0 mmol) and stirred overnight at RT. The solution was then filtered, and the filtrate was washed twice with saturated NH 4 Cl solution and water. Next, the organic phase was dried over sodium sulfate and filtered. The filtrate was concentrated by solvent evaporation, and then added drop-wise into dry Et 2 O and the product (α-azide-ω-tosyl PEG) was collected by filtration. Afterwards, freshly prepared sodium thioacetate (15.5 mmol) was added to a solution of α-azide-ω-tosyl PEG (3 mmol) in 100 ml dry DMF under inert atmosphere, and the mixture was stirred overnight at RT. After solvent evaporation, the residue was dissolved in CH 2 Cl 2 and treated with active charcoal for 2 h. The mixture was filtered, and the filtrate was concentrated to small volume by rotary evaporation, and was 
Synthesis of HS-PEG-NH 2 (IV)
PPh 3 (10.0 mmol) was added to a solution of III (3.0 mmol) in 50 ml dry MeOH, and the mixture was refluxed overnight under argon atmosphere. After cooling down the solvent removed by rotary evaporation, the resulting solid was dissolved in 10 ml CH 2 Cl 2 , and was added drop wise into dry Et 2 O and then IV was filtered. 1 
Synthesis of HS-PEG-NH-FA (V)
Folic acid (0.1 mmol) was added to a mixture of dicyclohexyl carbodiimide (DCC) (0.15 mmol) and N-hydroxy succinimide (NHS) (0.12 mmol) in 3 ml of dry DMSO, the mixture was left to stir at RT overnight in the dark. After the removal of the byproduct, dicyclohexyl urea, the filtrate was mixed with IV (0.11 mmol) and stirred at RT for 24 h. Then V was precipitated by adding dry Et 2 O, dried in vacuum, and was stored at -20°C. 
Synthesis of HS-PEG-FITC (VI)
FITC (10.0 μmol) and polymer IV (11.0 μmol) was dissolved in 2 ml EtOH and 2 ml CHCl 3 and stirred in the dark, under argon atmosphere. After 4 h, the product was precipitated by adding Et 2 O and dried. Then VI was filtered and stored at -20°C. @Au] NPs (5 mg/ml) was suspended in DMEM media at RT and placed inside the dialysis bag with a molecular cut-off of 14 kDa and then placed into DMEM cell culture media. The particles were stirred with sampling at 1, 2, 4, 6, 8, 12, 16 and 24 h. The samples were analyzed for FITC content using fluorescence spectrometer (perkin Elmer) at 488 nm. Increasing in FITC content outside the dialysis chamber indicates particle degradation. Therefore, at each time point 100 μl of supernatant was picked up as a sample and then, 100 μl of fresh medium was added to remain the volume at the previous scale. The absorbance of FITC was recorded, and the total release of FITC was calculated. To study physical stability of the synthesized NPs against aggregation, the particle sizes of 24, 48 , and 72 h of the treatment, the medium was removed and the cells were washed twice with PBS, and afterwards 20 μl of MTT (5 mg/ml) was added to each well. Plates were incubated for 3 h at 37°C. Then, 100 μl of DMSO was added to each well and left at 37°C for 15 min. The optical density was measured at 570 nm using a micro-plate reader (Biotek, USA). 
SF Loading and Releasing

Cell Viability by MTT Assay
Cell Apoptosis by Flow Cytometry
Apoptosis of MCF-7 cells was studied by flow cytometry using Annexin-V/PI staining because phosphatidyl serine is unprotected and detectable by Annexin-V at the external surface of the cells at initial stages of apoptosis. Briefly, cells were seeded into 6 well plates (10 5 
Statistical Analysis
Matlab was used for all statistical analysis. Data are expressed as mean ± SEM. Statistical analysis to detect differences between groups was done by using one-way analysis of variance (ANOVA) with p-value <0.05 to indicate statistically significant differences. Post-hoc pairwise comparisons of Tukey(-Kramer) and Bonferroni tests were preformed and the smaller of the two intervals was taken. Fig 1B and 1C) . The analysis of SEM and TEM images showed that the average size of the synthesized NPs is less than 40 nm. The particle size distribution function confirmed that the size of NPs was 37±2.1 nm, which indicates a small heterogeneity in the size of the particles.
Results
Preparation and Characterization of Nanocarrier
Energy dispersive X-ray (EDX) spectroscopy was done to investigate the presence of Au and Fe in the NPs. EDX spectrum of the NPs is presented in Fig 2, which confirms To confirm the existence of iron oxide-gold core shell, the powder X-Ray diffraction (XRD) experiment was used as an applicable technique. There were three bands in the XRD pattern which attributable to the corresponding reflections of the solid gold at 2θ = 44.67°, 51.72°, and 76.71°(JCPDS#89-3697). But, the characteristic bands of magnetic core no longer appeared in the XRD spectrum. The absence is due to the fact that all iron oxide NPs are coated with 2 nm thickness of gold [25, 38] .
In Since the existence of the magnetic NP in the designed NP would be a good candidate for in vivo therapy in animal model (using MRI), then it is important to synthesize the magneticcore-shell with sufficient superparamagnetic property. To investigate it, the magnetic (M) hysteresis loop of the same mass of the [Fe 3 O 4 @Au] and FITC/FA@[Fe 3 O 4 @Au] NPs were investigated while magnetic field (H) at RT was applied. As shown in Fig 3, @Au] NPs were 7.24 and 2.07 emu/g at RT, respectively. The lower magnetic saturation of later NPs could be due to the influence of the PEG group. Furthermore, the hysteresis loop for the samples were completely reversible. The reversibility in hysteresis loop confirms that no aggregation imposes to the NPs in the external magnetic field and the NPs exhibit superparamagnetic property. nm, respectively. The average size of both are less than 50 nm. Based on our measurement, NPs with and without drug are almost with small standard deviation in size (narrow particle size distribution function).
Another physical quantity which affects on cellular up take is the surface charge of synthesized NPs. The NPs with positive charge (size smaller than 100 nm) cross the cell membrane and readily taken up by cells [39] . The zeta potential of SF-loaded FITC/FA@[Fe 3 O 4 @Au] NP was measured and 9.47±4.6 mv was obtained which is suitable for cell membrane penetration.
Chemical and Physical Stability of FITC/FA@[Fe 3 O 4 @Au] NPs
To investigate the chemical stability of FITC/FA@[Fe 3 O 4 @Au] NPs, release of FITC from NPs was studied by UV-visible spectroscopy at 488 nm. The release of FITC could occurred due to the ligand exchange in the presence of a reductive media. The release profile was measured in two mediums including DMEM (Fig 4A) and glutathione (GSH). The releasing rate of FITC from FITC/FA@[Fe 3 O 4 @Au] during 24 h in DMEM shows a two-steps pattern. An initial burst release at the first 8 h which is followed by a relatively slower release during the next 16 h. At the first 8 h, the FITC-release was reached to around 17%, thereafter it remained almost steady through the next 16 h. At 24 h, the amount of FITC-release was about 18.87% in the cell culture medium (pH = 7.4). This implies that FITC/FA@[Fe 3 O 4 @Au] NPs which are suitable as drug carriers will reach to the cells with minimum lose of FITC (at 24 h). The release of FITC moiety from the NPs in 5% GSH at 24 h showed no significant change in compare to DMEM. To the best of our knowledge, the disulfide bonds are cleaved by reducing agents such as GSH. Our synthesized NPs contains FITC moiety without any linkage S-S bond. Therefore, it is clear why there was not observed a significant change in the release pro- (Fig 6A) . There is a significant (p-value <0.05) decrease in the percentage of cell viability at the concentrations of 1.5, 3 and 6 μmol/l at 48 h versus 24 h. Also, there is a significant decrease (p-value <0.05) in the percentage of cell viability at the concentrations of 0.75, 1.5, 3, 6, 12 and 24 μmol/l after 72 h versus 24 h. Finally, statistical analysis with the same p-value reveals that there is a significant decrease in the percentage of cell viability at the concentrations of 1.5 and 3 μmol/l after 72 h versus 48 h. Furthermore, at any time, there is no significant decrease in the percentage of cell 
Cellular Uptake
In order to investigate the cellular uptake, images of control cells (Fig 7A-7C ), incubated cells with free SF (Fig 7D-7F) , and incubated cells with FITC/FA@[Fe 3 O 4 @Au] NPs (Fig 7G-7I) were prepared. The emerged images of DAPI with bright field images (Fig 7B and 7E) , and FITC-channel (Fig 7I) (Fig 8A and 8D) , fluorescence image of FITC detection (Fig 8B and 8E) , and emerged images of FITC with bright field images (Fig 8C and 8F) , respectively. According to the Fig 8B and 8E, (Fig 9A-9F) . Based on the same colorbar corresponding the fluorescence intensity of FITC-emission, after 72 h, cells uptake more SF-loaded FITC/FA@ [Fe 3 O 4 @Au] NPs. From the images it is possible to evaluate whether the drug release occurs intracellularly following NPs uptake or the drug release occurs extracellularly prior to NPs uptake/delivery. The dynamics of the drug release at two different pH were studied to estimate the percentage of releasing at different environmental conditions. Since the pH of the release medium is merely close to the pH of PBS at 24 
Cell Apoptosis
A double staining flow cytometric assay using Annexin V/FITC (A), which reacts with viable cells, and propidium iodide (PI) was performed to quantify the apoptotic MCF-7 cells accurately. Fig 10A shows 
Discussion and Conclusions
We have designed, synthesized and characterized a novel and robust nano-magnetic gold DDS to improve the efficiency of SF delivery. The synthesized nano-magnetic vehicle was characterized by a number of techniques such as EDX, XRD, VSM, FT-IR, TGA, DLS, TEM, and SEM. Owing to the hydrophilicity behavior of PEG function as surface modifier, the aforementioned surface manipulations provide the convenient surface to encompass SF via the electrostatic interaction between the S = O bond from SF and the oxygen groups from hydrophilic PEG linker. Hence, in order to 1) overcome the SF-instability, 2) improve SF-delivery, and 3) control SF-release, the surface of NPs was manipulated with functionalized PEG.
In vitro cytotoxicity study (MTT assay) of MCF-cells showed that SF-loaded FITC/FA@ [Fe 3 O 4 @Au] NPs are more cytotoxic than free SF. The mechanism of induced appotosis in MCF-7 cells was revealed by double staining flow cytometric assay. Based on the statistical analysis of the obtained data, the rates of total apoptosis significantly were increased after loading onto the synthesized nano-magnetic vehicles in comparison with free SF. Following detection of apoptosis mechanism in cytotoxicity of SF-loaded FITC/FA@[Fe 3 O 4 @Au] NPs for MCF-7 cells, the expression rate of anti-apoptotic genes (bcl-2 and bcl-x L ) and pro-apoptotic genes (bax and bak) were quantified by Real-Time PCR technique. The expression rate of bcl-2 and bcl-x L genes significantly were decreased in comparison with untreated cells.
Notably, in vitro breast cancer study showed that FITC/FA@[Fe 3 O 4 @Au] NP would be a proper candidate nanocarrier for SF-delivery and provides a suitable and appropriate system for pH-dependent delivery of SF. These results would open new horizons to develop promising nano-DDSs to design further nanoparticle systems to improve the therapeutic effect of SF in the future.
